Effectiveness of TruScreen for detecting CIN2+ in women with ThinPrep cytologic test results indicating atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions

Future Oncol. 2023 Dec;19(37):2493-2504. doi: 10.2217/fon-2023-0297. Epub 2023 Dec 6.

Abstract

Objective: To evaluate the effectiveness of TruScreen (TS) for detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women with abnormal ThinPrep cytologic test (TCT) results. Methods: 466 women with atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) were enrolled and underwent TS, colposcopy and biopsy examination. Results: Compared with the high-risk human papillomavirus (hrHPV) test for CIN2+, significantly higher specificity of TS, combined TS and hrHPV (69.6 and 75.0 vs 36.8% in ASCUS; 59.0 and 69.9 vs 30.1% in LSIL), significantly higher positive predictive value of combined TS and hrHPV were observed (32.7 vs 24.6% in ASCUS; 47.9 vs 35.6% in LSIL). Conclusion: TS combined with hrHPV showed better performance in diagnosing CIN2+ in ASCUS/LSIL.

Keywords: ASCUS; CIN; LSIL; TruScreen; cervical cancer screening; cervical transformation zone.

MeSH terms

  • Atypical Squamous Cells of the Cervix*
  • Female
  • Humans
  • Papillomaviridae / genetics
  • Papillomavirus Infections* / diagnosis
  • Sensitivity and Specificity
  • Squamous Intraepithelial Lesions* / diagnosis
  • Uterine Cervical Dysplasia* / diagnosis
  • Uterine Cervical Neoplasms* / pathology
  • Vaginal Smears